NIH News Releases

Omalizumab treats multi-food allergy better than oral immunotherapy

High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab.

Mar 3, 2025 - 17:23
 0
Omalizumab treats multi-food allergy better than oral immunotherapy
High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab.
Read More

Tags:

Previous Article

Transplant programs hit record numbers of operations

Next Article

Boston Scientific to buy Sonivie for up to $540M

Related Posts

NIH-funded study finds cases of ME/CFS increase following SARS-CoV-2

NIH-funded study finds cases of ME/CFS increase followi...

Feb 9, 2025  0

Aging may change some brain cells more than others

Aging may change some brain cells more than others

Feb 9, 2025  0

Single dose of broadly neutralizing antibody protects macaques from H5N1 influenza

Single dose of broadly neutralizing antibody protects m...

Feb 11, 2025  0